Skip to main content

Table 3 Treatment-emergent adverse events occurring in ≥10% of patients in phase 1 (n = 43)

From: Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

Treatment-emergent AEs, n (%)

100 mg

150 mg

200 mg

300 mg

400 mg

500 mg

600 mg

All patients

n = 3

n = 6

n = 9

n = 6

n = 6

n = 7

n = 6

n = 43

Grade 1/2a

Grade 3/4a

Any AE

3 (100.0)

6 (100.0)

9 (100.0)

6 (100.0)

6 (100.0)

7 (100.0)

6 (100.0)

8 (18.6)

35 (81.4)

Diarrhea

2 (66.7)

2 (33.3)

5 (55.6)

3 (50.0)

6 (100.0)

7 (100.0)

6 (100.0)

28 (65.1)

3 (7.0)

Nausea

0

1 (16.7)

2 (22.2)

3 (50.0)

4 (66.7)

5 (71.4)

4 (66.7)

19 (44.2)

0

Vomiting

0

1 (16.7)

4 (44.4)

2 (33.3)

3 (50.0)

3 (42.9)

3 (50.0)

16 (37.2)

0

Fatigue

1 (33.3)

1 (16.7)

3 (33.3)

2 (33.3)

2 (33.3)

3 (42.9)

1 (16.7)

9 (20.9)

4 (9.3)

Edema peripheral

2 (66.7)

2 (33.3)

1 (11.1)

0

2 (33.3)

2 (28.6)

3 (50.0)

10 (23.3)

2 (4.7)

Pyrexia

1 (33.3)

2 (33.3)

2 (22.2)

1 (16.7)

2 (33.3)

2 (28.6)

2 (33.3)

9 (20.9)

3 (7.0)

Anemia

0

1 (16.7)

1 (11.1)

1 (16.7)

2 (33.3)

2 (28.6)

3 (50.0)

3 (7.0)

7 (16.3)

Constipation

2 (66.7)

2 (33.3)

2 (22.2)

1 (16.7)

2 (33.3)

1 (14.3)

1 (16.7)

11 (25.6)

0

Abdominal distension

0

0

2 (22.2)

1 (16.7)

3 (50.0)

1 (14.3)

2 (33.3)

9 (20.9)

0

Dyspnea

2 (66.7)

1 (16.7)

0

0

2 (33.3)

1 (14.3)

3 (50.0)

9 (20.9)

0

Asthenia

2 (66.7)

2 (33.3)

1 (11.1)

0

0

1 (14.3)

2 (33.3)

6 (14.0)

2 (4.7)

Decreased appetite

2 (66.7)

2 (33.3)

0

0

3 (50.0)

0

1 (16.7)

8 (18.6)

0

Epistaxis

2 (66.7)

1 (16.7)

1 (11.1)

2 (33.3)

1 (16.7)

0

1 (16.7)

7 (16.3)

1 (2.3)

Thrombocytopenia

1 (33.3)

2 (33.3)

0

1 (16.7)

2 (33.3)

1 (14.3)

1 (16.7)

2 (4.7)

6 (14.0)

Abdominal pain

1 (33.3)

1 (16.7)

1 (11.1)

1 (16.7)

2 (33.3)

0

1 (16.7)

6 (14.0)

1 (2.3)

Back pain

1 (33.3)

2 (33.3)

0

1 (16.7)

2 (33.3)

1 (14.3)

0

7 (16.3)

0

Insomnia

1 (33.3)

1 (16.7)

2 (22.2)

1 (16.7)

1 (16.7)

1 (14.3)

0

7 (16.3)

0

Hyperuricemia

1 (33.3)

1 (16.7)

0

0

0

1 (14.3)

3 (50.0)

5 (11.6)

1 (2.3)

Cardiac murmur

1 (33.3)

0

1 (11.1)

0

1 (16.7)

1 (14.3)

2 (33.3)

6 (14.0)

0

Dizziness

0

0

2 (22.2)

1 (16.7)

1 (16.7)

1 (14.3)

1 (16.7)

6 (14.0)

0

Night sweats

1 (33.3)

0

1 (11.1)

0

2 (33.3)

1 (14.3)

1 (16.7)

6 (14.0)

0

Neutropenia

1 (33.3)

2 (33.3)

0

1 (16.7)

1 (16.7)

0

0

2 (4.7)

3 (7.0)

Chills

0

2 (33.3)

0

0

1 (16.7)

1 (14.3)

1 (16.7)

5 (11.6)

0

Cough

1 (33.3)

1 (16.7)

1 (11.1)

1 (16.7)

1 (16.7)

0

0

5 (11.6)

0

Dehydration

0

1 (16.7)

0

0

2 (33.3)

1 (14.3)

1 (16.7)

5 (11.6)

0

Hyperbilirubinemia

1 (33.3)

1 (16.7)

1 (11.1)

1 (16.7)

1 (16.7)

0

0

5 (11.6)

0

Pain in extremity

3 (100.0)

0

0

1 (16.7)

0

0

1 (16.7)

5 (11.6)

0

Petechiae

2 (66.7)

2 (33.3)

0

0

0

1 (14.3)

0

5 (11.6)

0

Skin lesion

0

4 (66.7)

1 (11.1)

0

0

0

0

5 (11.6)

0

Upper respiratory tract infection

0

2 (33.3)

2 (22.2)

1 (16.7)

0

0

0

5 (11.6)

0

  1. aWorst grade during treatment